Buy Xultophy Insulin Injection Online | No Prescription Needed | USA, Canada, Australia, UK

Description

What is Xultophy® 100/3.6?

Buy Xultophy online® 100/3.6 is a once-daily combination of basal insulin (insulin degludec) and a GLP-1 receptor agonist (liraglutide) for adults with type 2 diabetes.

Selected Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

• Liraglutide, one of the components of Xultophy^® 100/3.6, causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice.
• Xultophy^® 100/3.6 is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Buy Xultophy online

Indications and Limitations of Use

Xultophy^® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Buy Xultophy online

• Xultophy^® 100/3.6 is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.
• Xultophy^® 100/3.6 is not recommended for use in combination with any other product containing liraglutide or another GLP-1 receptor agonist (GLP-1 RA).
• Xultophy^® 100/3.6 is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Buy Xultophy online
• Xultophy^® 100/3.6 has not been studied in combination with prandial insulin.

Contraindications

• Xultophy^® 100/3.6 is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Xultophy^® 100/3.6, either of the active substances or any of its excipients. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with liraglutide, one of the components of Xultophy^® 100/3.6. Buy Xultophy online

Warnings and Precautions

• Risk of Thyroid C-cell Tumors: If serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging, the patient should be further evaluated.
• Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide postmarketing. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting).
• Never Share a Xultophy^® 100/3.6 Pen Between Patients, even if the needle is changed. Sharing of the pen poses a risk for transmission of blood-borne pathogens.
• Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia.
• Overdose Due to Medication Errors: Instruct patients to check the label before each injection since accidental mix-ups with insulin-containing products can occur. Do not administer more than 50 units of Xultophy^® 100/3.6 daily. Do not exceed the 1.8 mg maximum recommended dose of liraglutide or use it with other GLP-1 RAs.
• Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin-containing products, including Xultophy^® 100/3.6, and may be life-threatening. Increase monitoring with changes to dose, co-administered glucose lowering medications, meal pattern, and physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment.
• Acute Kidney Injury: Acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis, have been reported postmarketing for liraglutide, usually in association with nausea, vomiting, diarrhea, or dehydration. Advise patients of the potential risk of dehydration due to gastrointestinal adverse reactions and take precautions to avoid fluid depletion.
• Hypersensitivity and Allergic Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, angioedema, bronchospasm, hypotension, and shock can occur. If a hypersensitivity reaction occurs, discontinue and treat per standard of care. Anaphylaxis and angioedema have been reported with other GLP-1 RAs. Use caution in a patient with a history of anaphylaxis or angioedema with other GLP-1 RAs because it is unknown whether such patients will be predisposed to these reactions with Xultophy^® 100/3.6.
• Acute Gallbladder Disease: In a cardiovascular outcomes trial (LEADER trial) 3.1% of patients treated with liraglutide, one of the components of Xultophy^® 100/3.6, versus 1.9% of placebo-treated patients reported an acute event of gallbladder diseases, such as cholelithiasis or cholecystitis. The majority of events required hospitalization or cholecystectomy. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
• Hypokalemia: All insulin-containing products, including Xultophy^® 100/3.6 can lead to life-threatening hypokalemia, which may then cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
• Fluid Retention and Congestive Heart Failure: Patients using insulin-containing products, including Xultophy^® 100/3.6, with thiazolidinediones (TZDs) should be observed for signs and symptoms of heart failure. If heart failure develops, dosage reduction or discontinuation of the TZD must be considered.

Adverse Reactions

• The most common adverse reactions, reported in? 5% of patients treated with Xultophy^® 100/3.6 are nasopharyngitis, headache, nausea, diarrhea, increased lipase, and upper respiratory tract infection.

Drug Interactions

• Certain drugs may affect glucose metabolism, requiring dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).
• Liraglutide-containing products, including Xultophy^® 100/3.6, cause a delay in gastric emptying and thereby have the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with liraglutide-containing products.

Use in Specific Populations

• Xultophy^® 100/3.6 should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.